新适应症-话题@MedSci

#新适应症#

62篇内容 | 2569人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1416217, encodeId=39f5141621ea8, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=君实生物特瑞普利单抗用于治疗尿路上皮癌患者的新适应症上市申请获受理, objectType=article, longId=193780, objectId=7cfe193e80fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7cfe193e80fe, replyNumber=0, likeNumber=72, createdTime=2020-05-10, rootId=0, userName=sunyl08, userId=613c3147617, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7cfe193e80fe, moduleTitle=君实生物特瑞普利单抗用于治疗尿路上皮癌患者的新适应症上市申请获受理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7cfe193e80fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416216, encodeId=3a8b14162164a, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=信迪利单抗申请一线治疗非鳞状非小细胞肺癌新适应症, objectType=article, longId=192965, objectId=ea1f19296574, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea1f19296574, replyNumber=0, likeNumber=116, createdTime=2020-04-27, rootId=0, userName=sunyl08, userId=613c3147617, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea1f19296574, moduleTitle=信迪利单抗申请一线治疗非鳞状非小细胞肺癌新适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea1f19296574)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416215, encodeId=feb91416215e7, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=连花清瘟获批新适应症！治疗新冠肺炎轻型、普通型患者, objectType=article, longId=192258, objectId=2e6b19225867, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e6b19225867, replyNumber=0, likeNumber=76, createdTime=2020-04-16, rootId=0, userName=sunyl08, userId=613c3147617, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e6b19225867, moduleTitle=连花清瘟获批新适应症！治疗新冠肺炎轻型、普通型患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e6b19225867)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416214, encodeId=a7db1416214d9, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=加拿大卫生部批准卡那列净的新适应症，以降低2型糖尿病患者肾病相关风险, objectType=article, longId=186986, objectId=f35818698644, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f35818698644, replyNumber=0, likeNumber=66, createdTime=2020-01-31, rootId=0, userName=sunyl08, userId=613c3147617, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f35818698644, moduleTitle=加拿大卫生部批准卡那列净的新适应症，以降低2型糖尿病患者肾病相关风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f35818698644)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416213, encodeId=3e5c141621352, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=原研全人源阿达木单抗获批新适应症，为克罗恩病患者带来新的曙光!, objectType=article, longId=186386, objectId=7b2a186386f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b2a186386f6, replyNumber=0, likeNumber=102, createdTime=2020-01-18, rootId=0, userName=sunyl08, userId=613c3147617, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b2a186386f6, moduleTitle=原研全人源阿达木单抗获批新适应症，为克罗恩病患者带来新的曙光!, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b2a186386f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416212, encodeId=4a4a1416212f2, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=罗氏骁悉®狼疮性肾炎新适应症在华上市，同步启动卵巢关爱项目, objectType=article, longId=183846, objectId=778f1838464b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=778f1838464b, replyNumber=0, likeNumber=67, createdTime=2019-12-01, rootId=0, userName=sunyl08, userId=613c3147617, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=778f1838464b, moduleTitle=罗氏骁悉®狼疮性肾炎新适应症在华上市，同步启动卵巢关爱项目, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=778f1838464b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416211, encodeId=ea3514162113c, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=RTOR项目比优先审评还快！7个肿瘤药新适应症已获批, objectType=article, longId=167026, objectId=6ba316e0263d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ba316e0263d, replyNumber=0, likeNumber=95, createdTime=2019-05-29, rootId=0, userName=sunyl08, userId=613c3147617, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ba316e0263d, moduleTitle=RTOR项目比优先审评还快！7个肿瘤药新适应症已获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ba316e0263d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416210, encodeId=d5861416210f4, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=刚刚，Keytruda在中国获批新适应症，一线治疗非鳞状NSCLC, objectType=article, longId=163233, objectId=c8c0163233da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c8c0163233da, replyNumber=0, likeNumber=74, createdTime=2019-03-31, rootId=0, userName=sunyl08, userId=613c3147617, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c8c0163233da, moduleTitle=刚刚，Keytruda在中国获批新适应症，一线治疗非鳞状NSCLC, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c8c0163233da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416209, encodeId=13f314162092f, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=已上市抗肿瘤药物增加新适应症技术指导原则, objectType=article, longId=155111, objectId=18ff1551117c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18ff1551117c, replyNumber=0, likeNumber=106, createdTime=2018-12-06, rootId=0, userName=sunyl08, userId=613c3147617, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18ff1551117c, moduleTitle=已上市抗肿瘤药物增加新适应症技术指导原则, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18ff1551117c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416208, encodeId=9e5c141620847, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=新型降糖药利时敏新适应症在华获批, objectType=article, longId=154279, objectId=6ed11542e9f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ed11542e9f7, replyNumber=0, likeNumber=79, createdTime=2018-11-25, rootId=0, userName=sunyl08, userId=613c3147617, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ed11542e9f7, moduleTitle=新型降糖药利时敏新适应症在华获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ed11542e9f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416207, encodeId=526e141620e3e, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=赛诺菲中国糖尿病产品线再添“新军”，新型降糖药利时敏®新适应症在华获批, objectType=article, longId=154276, objectId=ba471542e607, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba471542e607, replyNumber=0, likeNumber=88, createdTime=2018-11-25, rootId=0, userName=sunyl08, userId=613c3147617, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba471542e607, moduleTitle=赛诺菲中国糖尿病产品线再添“新军”，新型降糖药利时敏®新适应症在华获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ba471542e607)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416206, encodeId=195f141620631, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=美国食品药品监督管理局批准Opdivo®新适应症成为全球近20年来用于经治小细胞肺癌的新药, objectType=article, longId=147166, objectId=a7ea14e16667, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7ea14e16667, replyNumber=0, likeNumber=89, createdTime=2018-08-23, rootId=0, userName=sunyl08, userId=613c3147617, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7ea14e16667, moduleTitle=美国食品药品监督管理局批准Opdivo®新适应症成为全球近20年来用于经治小细胞肺癌的新药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a7ea14e16667)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416205, encodeId=e8f9141620504, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=K药今日正式登陆中国，新适应症加速获批, objectType=article, longId=147144, objectId=0a7d14e14421, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a7d14e14421, replyNumber=0, likeNumber=83, createdTime=2018-08-22, rootId=0, userName=sunyl08, userId=613c3147617, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a7d14e14421, moduleTitle=K药今日正式登陆中国，新适应症加速获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a7d14e14421)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416204, encodeId=a6a114162040e, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=勃林格殷格翰泰毕全®（达比加群酯）新适应症获CFDA批准, objectType=article, longId=121092, objectId=76a6121092e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76a6121092e6, replyNumber=0, likeNumber=128, createdTime=2017-11-24, rootId=0, userName=sunyl08, userId=613c3147617, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76a6121092e6, moduleTitle=勃林格殷格翰泰毕全®（达比加群酯）新适应症获CFDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76a6121092e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416203, encodeId=23571416203f9, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=靶向新药伊布替尼获批新适应症——复发难治性边缘区淋巴瘤（MZL）, objectType=article, longId=116548, objectId=8f8f1165488a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f8f1165488a, replyNumber=0, likeNumber=99, createdTime=2017-10-19, rootId=0, userName=sunyl08, userId=613c3147617, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f8f1165488a, moduleTitle=靶向新药伊布替尼获批新适应症——复发难治性边缘区淋巴瘤（MZL）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f8f1165488a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416202, encodeId=bcc2141620285, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=新剂型，新适应症！奥拉帕尼获批二线维持治疗卵巢癌, objectType=article, longId=110888, objectId=dbc4110888e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbc4110888e5, replyNumber=0, likeNumber=67, createdTime=2017-08-27, rootId=0, userName=sunyl08, userId=613c3147617, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbc4110888e5, moduleTitle=新剂型，新适应症！奥拉帕尼获批二线维持治疗卵巢癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dbc4110888e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416201, encodeId=bda2141620193, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=强生为Darzalex申请新适应症，进军多发性骨髓瘤二线治疗, objectType=article, longId=75557, objectId=f64ae5557dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f64ae5557dd, replyNumber=0, likeNumber=66, createdTime=2016-08-22, rootId=0, userName=sunyl08, userId=613c3147617, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f64ae5557dd, moduleTitle=强生为Darzalex申请新适应症，进军多发性骨髓瘤二线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f64ae5557dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416200, encodeId=69d01416200c3, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=喜讯！默沙东PD-1免疫疗法Keytruda治疗晚期非小细胞肺癌（NSCLC）新适应症获CHMP支持批准, objectType=article, longId=71750, objectId=6a53e17507d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a53e17507d, replyNumber=0, likeNumber=116, createdTime=2016-06-30, rootId=0, userName=sunyl08, userId=613c3147617, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a53e17507d, moduleTitle=喜讯！默沙东PD-1免疫疗法Keytruda治疗晚期非小细胞肺癌（NSCLC）新适应症获CHMP支持批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a53e17507d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416199, encodeId=b72b141619976, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=阿斯利康心血管药Brilinta未能达到新适应症III期临床主要终点, objectType=article, longId=65585, objectId=4f7365585cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f7365585cc, replyNumber=0, likeNumber=100, createdTime=2016-03-28, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f7365585cc, moduleTitle=阿斯利康心血管药Brilinta未能达到新适应症III期临床主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4f7365585cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416198, encodeId=47d214161984c, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=拜耳眼科药物Eylea视网膜静脉阻塞继发黄斑水肿（ME-RVO）新适应症获日本批准, objectType=article, longId=52572, objectId=bff4525e2dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bff4525e2dc, replyNumber=0, likeNumber=79, createdTime=2015-07-01, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bff4525e2dc, moduleTitle=拜耳眼科药物Eylea视网膜静脉阻塞继发黄斑水肿（ME-RVO）新适应症获日本批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bff4525e2dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

新适应症

2020-05-29

sunyl08 (审核中...)

前往app查看评论内容

#新适应症#

君实生物特瑞普利单抗用于治疗尿路上皮癌患者的新适应症上市申请获受理

2020-05-10

sunyl08 (审核中...)

前往app查看评论内容

#新适应症#

信迪利单抗申请一线治疗非鳞状非小细胞肺癌新适应症

2020-04-27

sunyl08 (审核中...)

前往app查看评论内容

#新适应症#

连花清瘟获批新适应症！治疗新冠肺炎轻型、普通型患者

2020-04-16

sunyl08 (审核中...)

前往app查看评论内容

#新适应症#

加拿大卫生部批准卡那列净的新适应症，以降低2型糖尿病患者肾病相关风险

2020-01-31

sunyl08 (审核中...)

前往app查看评论内容

#新适应症#

原研全人源阿达木单抗获批新适应症，为克罗恩病患者带来新的曙光!

2020-01-18

sunyl08 (审核中...)

前往app查看评论内容

#新适应症#

罗氏骁悉®狼疮性肾炎新适应症在华上市，同步启动卵巢关爱项目

2019-12-01

sunyl08 (审核中...)

前往app查看评论内容

#新适应症#

RTOR项目比优先审评还快！7个肿瘤药新适应症已获批

2019-05-29

sunyl08 (审核中...)

前往app查看评论内容

#新适应症#

刚刚，Keytruda在中国获批新适应症，一线治疗非鳞状NSCLC

2019-03-31

sunyl08 (审核中...)

前往app查看评论内容

#新适应症#

已上市抗肿瘤药物增加新适应症技术指导原则

2018-12-06

sunyl08 (审核中...)

前往app查看评论内容

#新适应症#

新型降糖药利时敏新适应症在华获批

2018-11-25

sunyl08 (审核中...)

前往app查看评论内容

#新适应症#

赛诺菲中国糖尿病产品线再添“新军”，新型降糖药利时敏®新适应症在华获批

2018-11-25

sunyl08 (审核中...)

前往app查看评论内容

#新适应症#

美国食品药品监督管理局批准Opdivo®新适应症成为全球近20年来用于经治小细胞肺癌的新药

2018-08-23

sunyl08 (审核中...)

前往app查看评论内容

#新适应症#

K药今日正式登陆中国，新适应症加速获批

2018-08-22

sunyl08 (审核中...)

前往app查看评论内容

#新适应症#

勃林格殷格翰泰毕全®（达比加群酯）新适应症获CFDA批准

2017-11-24

sunyl08 (审核中...)

前往app查看评论内容

#新适应症#

靶向新药伊布替尼获批新适应症——复发难治性边缘区淋巴瘤（MZL）

2017-10-19

sunyl08 (审核中...)

前往app查看评论内容

#新适应症#

新剂型，新适应症！奥拉帕尼获批二线维持治疗卵巢癌

2017-08-27

sunyl08 (审核中...)

前往app查看评论内容

#新适应症#

强生为Darzalex申请新适应症，进军多发性骨髓瘤二线治疗

2016-08-22

sunyl08 (审核中...)

前往app查看评论内容

#新适应症#

喜讯！默沙东PD-1免疫疗法Keytruda治疗晚期非小细胞肺癌（NSCLC）新适应症获CHMP支持批准

2016-06-30

docwu2019 (审核中...)

前往app查看评论内容

#新适应症#

阿斯利康心血管药Brilinta未能达到新适应症III期临床主要终点

2016-03-28

docwu2019 (审核中...)

前往app查看评论内容

#新适应症#

拜耳眼科药物Eylea视网膜静脉阻塞继发黄斑水肿（ME-RVO）新适应症获日本批准

2015-07-01

科室
- - 订阅+
  - 更多科室
工具
服务